Compass Therapeutics Inc (NAS:CMPX)
$ 2.34 +0.020 (+0.86%) Market Cap: 421.41 Mil Enterprise Value: 236.51 Mil PE Ratio: 0 PB Ratio: 2.26 GF Score: 23/100

Compass Therapeutics Inc. at JPMorgan Healthcare Conference Transcript

Jan 14, 2026 / 03:30PM GMT
Release Date Price: $6.04 (+8.24%)
Sherry Yang
JP Morgan - Analyst

Good morning, everyone. Welcome to day three of the JPM Healthcare Conference. My name is Sherry Yang, an associate in the Healthcare Investment Banking Group, and it's my pleasure to be introducing Compass Therapeutics today. We have Tom Schuetz here, the CEO with me on stage. Let's give a warm welcome to Tom to the podium.

Thomas Schuetz
Compass Therapeutics Inc. - Chief Executive Officer, Vice Chairman of the Board

Thanks, Sherry and thanks to JP Morgan for inviting us to present at the meeting this year. Just very briefly, I will be making forward-looking statements today and I would refer you to our regulatory filings if you have any questions about those.

Compass Therapeutics, we're based in Boston, Mass. We're a monoclonal antibody discovery and development company in oncology. We have 3 drugs in the clinic, and I'm going to talk about each of these drugs today because we've developed very important efficacy signals for each one of our drugs that's in the clinic. And this quarter, our 4th drug is going to enter

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot